newsfilter
← Latest News
Business Wire·

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

- PROSERA Phase 3 in PAH on Track for Topline Data Readout in Fourth Quarter of 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Second Half of 2025 - - Seralutinib Receives Orphan Drug Designation